The work of Yue et al. [53] describes a therapy using HC-2G4S (BsAb)—a bispecific antibody directed against two promising GC biomarkers, HER2 and CLDN18.2, which eliminates gastric cancer cells (expressing these two antigens) by enhancing the effector function of the immune system. This evidence concerns the gene ERBB2 and gastric cancer.